Less than one in 10 people eligible to benefit from GLP-1 drugs like Wegovy are able to get them, caution the World Health Organization as it releases its first recommendations on the medications.
With in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for increased and just availability to this class of drugs.
Per projections, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"Our latest guidelines affirms that obesity is a long-term condition that can be managed with holistic and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are significant hurdles to widespread availability to the jabs that can help people shift considerable weight, says the agency.
Weight-Loss Drug Supply Crisis
Even under the current most optimistic case, the production of such drugs might only reach about 100 million people – less than 10% of the global need, per the health organization.
The recommendation encourages countries and companies to widen access, through strategies including patent sharing.
Exclusive production rights on semaglutide – the primary ingredient of the drug Wegovy – is due to expire in multiple nations in 2026.
How Obesity Jabs Function
The injections imitate a biological compound to delay gastric emptying, reduce hunger and enhance feelings of fullness so people eat less.
Patients usually begin shedding pounds after several weeks of commencing the once-weekly jabs.
Evidence suggests patients may see weight return within a year of stopping the treatment, when their typical food cravings come back.
To be above a healthy weight elevates your likelihood for developing health problems, including diabetes, cardiovascular issues, brain attack, and specific cancers.
Obesity concerns individuals in every country and was associated with 3.7 million deaths worldwide in 2024, per the health agency.
